Fluoxetine

Generic Name: Fluoxetine

Brand Names: Prozac, Sarafem, Symbyax

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₁₈F_₃NO

CAS Number: 54910-89-3

Unique Ingredient Identifier: 01K63SUP8D

Background: Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies.

Indication: Fluoxetine is indicated for both acute and maintenance treatment of major depressive disorder, obsessive compulsive disorder, and bulimia nervosa; however, it is only indicated for acute treatment of panic disorder independent of whether agoraphobia is present. Fluoxetine may also be used in combination with olanzapine to treat depression related to Bipolar I Disorder, and treatment resistant depression. Fluoxetine is additionally indicated for the treatment of female patients with premenstrual dysphoric disorder (PMDD).

Associated Conditions: Alcohol Dependency, Anorexia Nervosa (AN), Bulimia Nervosa, Cataplexy, Depression, Major Depressive Disorder (MDD), Major depressive disorder, recurrent episode, Myoclonus, Obesity, Obsessive Compulsive Disorder (OCD), Panic Disorder With Agoraphobia, Panic disorder without agoraphobia, Premature Ejaculation, Premenstrual Dysphoric Disorder (PMDD)

Associated Therapies: Maintenance therapy

Clinical Trials

SMART-DAPPER: Leveraging the Depression And Primary-care Partnership for Effectiveness-implementation Research Project

Not Applicable

Completed

Conditions: Trauma
Depression, Unipolar
Posttraumatic Stress Disorder

Interventions: Behavioral: Interpersonal Psychotherapy
Drug: Fluoxetine

First Posted Date: 2018-03-15

Last Posted Date: 2024-05-10

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 2162

Registration Number: NCT03466346

Locations: 🇰🇪
Kisumu County Hospital, Kisumu, Kenya
🇰🇪
Lumumba Health Center, Kisumu, Kenya
🇰🇪
Jaramogi Oginga Odinga Teaching and Referral Hospital (JOOTRH), Kisumu, Kenya

The Effect of G-DBT on the Patients With BN : A Multicenter Randomized Controlled Study

Not Applicable

Completed

Conditions: Feeding and Eating Disorders

Interventions: Behavioral: Dialectical Behavioral Group Therapy

First Posted Date: 2018-03-06

Last Posted Date: 2022-10-04

Lead Sponsor: Shanghai Mental Health Center

Target Recruit Count: 101

Registration Number: NCT03455088

Locations: 🇨🇳
Shanghai Mental Health Center, Shanghai, Shanghai, China

Fluoxetine Opens Window to Improve Motor Recovery After Stroke

Phase 2

Completed

Conditions: Brain Ischemia
Cerebrovascular Disorders
Central Nervous System Diseases
Nervous System Diseases
Brain Infarction
Stroke
Cerebral Infarction
Brain Diseases
Vascular Diseases
Cerebrovascular Accident

Interventions: Drug: Fluoxetine Hydrochloride
Other: Placebo
Behavioral: Exercise Program

First Posted Date: 2018-02-27

Last Posted Date: 2022-11-04

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 52

Registration Number: NCT03448159

Locations: 🇨🇦
University of Calgary, Calgary, Alberta, Canada
🇨🇦
University of British Columbia & GF Strong Centre, Vancouver, British Columbia, Canada
🇨🇦
Riverview Health Centre, Winnipeg, Manitoba, Canada

and more 5 locations

OxSYPan: Oxford Study With Young People on Antidepressants

Not Applicable

Completed

Conditions: Depression

Interventions: Other: Peppermint syrup
Drug: Fluoxetine

First Posted Date: 2018-02-19

Last Posted Date: 2018-02-20

Lead Sponsor: University of Oxford

Target Recruit Count: 32

Registration Number: NCT03436173

Identifying and Treating Depression in Hemodialysis Patients

Phase 4

Completed

Conditions: Depression
Hemodialysis-Induced Symptom

Interventions: Drug: Fluoxetine

First Posted Date: 2018-01-05

Last Posted Date: 2024-10-17

Lead Sponsor: MetroHealth Medical Center

Target Recruit Count: 16

Registration Number: NCT03390933

Locations: 🇺🇸
MetroHealth Medical Center, Cleveland, Ohio, United States

The Effects of Fluoxetine And/or DHEA

Early Phase 1

Recruiting

Conditions: Type 1 Diabetes Mellitus

Interventions: Drug: Fluoxetine and DHEA
Drug: Placebo Oral Tablet
Drug: Fluoxetine
Drug: DHEA

First Posted Date: 2017-07-25

Last Posted Date: 2024-11-05

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 60

Registration Number: NCT03228732

Locations: 🇺🇸
University of Maryland, Baltimore, Maryland, United States

Multi-Dimensional Diagnosis,Individualized Therapy,and Management Technique for Major Depressive Disorder:Based on Clinical and Pathological Characteristics

Phase 4

Conditions: Depressive Disorder

Interventions: Combination Product: fluoxetine + cognitive-behavioral treatment（CBT）
Drug: fluoxetine + Amfebutamone
Combination Product: physical treatment+fluoxetine+amfebutamone
Combination Product: Cognitive behavior treatment +fluvoxamine
Drug: Lithium+fluvoxamine
Combination Product: fluvoxamine + lithium + physical therapy
Drug: Mirtazapine/SNRIs
Combination Product: mirtazapine+ Cognitive behavior treatment
Drug: mirtazapine + SNRIs
Combination Product: mirtazapine + SNRIs + physical therapy
Other: TAU(treat as usual)
Drug: Fluoxetine
Drug: Fluvoxamine

First Posted Date: 2017-07-17

Last Posted Date: 2017-10-10

Lead Sponsor: Shanghai Mental Health Center

Target Recruit Count: 800

Registration Number: NCT03219008

Locations: 🇨🇳
ShanghaiMHC, Shanghai, China

Randomized Clinical Trial of a Mindfulness Based Intervention in Generalized Anxiety Disorder

Not Applicable

Completed

Conditions: Generalized Anxiety Disorder

Interventions: Behavioral: Body in Mind Training (BMT)
Drug: Fluoxetine
Behavioral: Quality of Life Group

First Posted Date: 2017-03-07

Last Posted Date: 2019-02-27

Lead Sponsor: Hospital de Clinicas de Porto Alegre

Target Recruit Count: 200

Registration Number: NCT03072264

Locations: 🇧🇷
Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil

Abnormal Ventilatory Response to Carbon Dioxide: a Potential Biomarker for Seizure Induced Respiratory Depression & Modification by SSRI

Phase 2

Completed

Conditions: Epilepsy
SUDEP

Interventions: Drug: Placebo
Drug: Fluoxetine

First Posted Date: 2016-10-11

Last Posted Date: 2020-05-04

Lead Sponsor: Rup Kamal Sainju

Target Recruit Count: 30

Registration Number: NCT02929667

Locations: 🇺🇸
Univeristy of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
🇺🇸
The Univeristy of Iowa Hospitals and Clinics, Iowa City, Iowa, United States

Measurement-based Care for Depression in Resource-Poor Settings

Phase 4

Completed

Conditions: Major Depression

Interventions: Behavioral: Enhanced Usual Care
Drug: Fluoxetine

First Posted Date: 2016-09-27

Last Posted Date: 2016-12-01

Lead Sponsor: Florida International University

Target Recruit Count: 140

Registration Number: NCT02916238

Locations: 🇭🇹
GHESKIO Centers, Port-au-Prince, Haiti

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy